Compare NWE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | BLTE |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2023 | 2021 |
| Metric | NWE | BLTE |
|---|---|---|
| Price | $69.87 | $173.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $60.83 | ★ $181.14 |
| AVG Volume (30 Days) | ★ 502.6K | 176.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $1,610,559,000.00 | N/A |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $3.61 | $218.41 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $50.46 | $49.00 |
| 52 Week High | $72.21 | $200.00 |
| Indicator | NWE | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 48.43 |
| Support Level | $65.84 | $168.00 |
| Resistance Level | $71.10 | $174.78 |
| Average True Range (ATR) | 1.64 | 8.58 |
| MACD | 0.03 | -2.07 |
| Stochastic Oscillator | 48.46 | 25.80 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric utility operations segment.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.